Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

Inclusion Criteria:

* Men or women
* Body mass index \> 19 and \< 28.5 Kg/m2
* Is able to understand the Informed Consent Form (ICF)

Exclusion Criteria:

* Women in their menstrual period;
* Diseases that interfere with the absorption, distribution and excretion of drugs, such as history or presence of hepatic or renal diseases;
* Presence of active genital lesions or sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, Human Papillomavirus, and others) that impair analysis of local adverse effects on the genitalia;
* History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patients with heart disease (including a history of angina and/or heart failure) and nephropathies;
* Findings on ECG and/or laboratory tests that, in the investigator's judgment, are considered the research volunteer's participation or may interfere with the analysis of the study of the study;
* Blood pressure (BP) outside the limits considered safe: systolic BP (SBP) 90 - 140 mmHg and diastolic BP diastolic BP (DBP) 60 - 90 mmHg, except for situations such as "white coat syndrome";
* Any disease or condition or physical finding that the investigator considers significant and that increases the risk
* Any disease or condition or physical finding that the investigator considers significant and that increases the risk of participation of the research volunteer or may interfere with the results.